Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study

por Verver, D, van der Veldt, AAM, van Akkooi, ACJ, Verhoef, C, Grünhagen, DJ, Louwman, WJ
Publicado 2019

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

por Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., Uyl-de Groot, C.A.
Publicado 2021